- Home
- XXI vs VRDN Comparison
XXI vs VRDN Comparison
Compare XXI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | VRDN |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XXI | VRDN |
|---|---|---|
| Price | $5.59 | $22.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $36.75 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $857.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.15 | $13.18 |
| 52 Week High | $11.49 | $34.29 |
Technical Indicators
Market Signals| Indicator | XXI | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 62.22 |
| Support Level | $5.02 | $21.40 |
| Resistance Level | $5.71 | $23.40 |
| Average True Range (ATR) | 0.33 | 0.98 |
| MACD | -0.10 | 0.59 |
| Stochastic Oscillator | 10.25 | 81.83 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.